|[September 23, 2013]
TGR BioSciences Announces License Agreement With Abcam
ADELAIDE, Australia --(Business Wire)--
TGR BioSciences Pty Ltd (TGR), a leading developer of advanced
cell-based assay technologies, is pleased to announce a license
agreement with Abcam plc, of Cambridge, UK, a producer and distributor
of high quality protein research tools. Under the agreement Abcam will
develop and manufacture immunoassay products that incorporate TGR's
proprietary CaptSure™ assay technology. Immunoassays incorporating
CaptSure are highly sensitive, offer considerable time savings, and are
easy to perform when compared with conventional sandwich immunoassays.
James Murray, General Manager of Abcam Eugene commented: "We are pleased
to have signed the license agreement with TGR. This innovative
technology will enable Abcam to continue to develop its high quality
immunoassay range by providing even greater choice to customers."
"We're extremely pleased that Abcam, a company at the forefront of
product supply and support, has recognised the significant advantages
afforded by our CaptSure immunoassay technology," says Anne Hinton, CEO
at TGR BioSciences. "Abcam is recognized around the world for providing
the highest quality products and services to the Life Science community,
and we are very excited to see Abcam incorporating our technology in
their immunoassay products."
About TGR BioSciences:
TGR BioSciences Pty Ltd (TGR) is an innovative private biotechnology
company based in Adelaide, South Australia, specializing in the
development of immunoassay technologies and products to serve the global
research and discovery markets TGR has on market a broad portfolio of
state-of-the-art assays for cell-based analysis of GPCRs, kinases and
cell signalling pathways, supplying major pharmaceutical and
biotechnology companies, and academic laboratories worldwide. TGR is
actively developing further novel cell-based analysis technologies to
advance research in other key therapeutic areas.
For more information, please visit www.tgrbio.com.
About the CaptSure™ technology:
TGR's proprietary CaptSure™ technology enables solution-phase delivery
of antibody pairs in sandwich immunoassays, allowing the simultaneous
formation and immobilisation of the analyte immunocomplex in a single
assay incubation. Assays can be run in as little as 1 hour, require only
a single wash cycle, and provide an extremely sensitive means for
quantitation of proteins. Furthermore, there is no requirement for
specialized instrumentation, with the assays using standard laboratory
plate readers for signal detection.
Abcam plc is a provider of protein research tools and services, with an
unrivalled range of products and expert technical support, enabling
scientists to analyse living cells at the molecular level and improving
the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of
reagents and tools, with the most comprehensive, honest and up-to-date
datasheets and customer reviews, fast delivery and helpful customer
service & technical support. The Company's catalogue evolves with
scientific research trends and is growing each year to provide customers
with products to meet their research needs. The range now includes
primary and secondary antibodies, proteins, peptides, lysates,
biochemicals, immunoassays and other kits. Abcam also supports its
customers by hosting a range of global scientific events, forums and
webinars, providing opportunities for scientists to get together and
present their work
Headquartered in Cambridge, UK, Abcam has global subsidiary offices
enabling local services, mulit-language support and next-day delivery in
over 130 countries. The Company was founded in 1998, and now employs
over 680 FTEs. Abcam was admitted to AIM in 2005 (AIM:ABC).
To find out more, please visit www.abcam.com.
About Abcam Eugene:
Formerly known as MitoSciences, Abcam Eugene is a centre of excellence
for assay development, supporting critical research areas in cancer,
neurodegeneration and metabolic disorders.
[ Back To Technology News's Homepage ]